» Articles » PMID: 23132303

The Complexity of Prostate Cancer: Genomic Alterations and Heterogeneity

Overview
Journal Nat Rev Urol
Specialty Urology
Date 2012 Nov 8
PMID 23132303
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

Although prostate cancer is the most common malignancy to affect men in the Western world, the molecular mechanisms underlying its development and progression remain poorly understood. Like all cancers, prostate cancer is a genetic disease that is characterized by multiple genomic alterations, including point mutations, microsatellite variations, and chromosomal alterations such as translocations, insertions, duplications, and deletions. In prostate cancer, but not other carcinomas, these chromosome alterations result in a high frequency of gene fusion events. The development and application of novel high-resolution technologies has significantly accelerated the detection of genomic alterations, revealing the complex nature and heterogeneity of the disease. The clinical heterogeneity of prostate cancer can be partly explained by this underlying genetic heterogeneity, which has been observed between patients from different geographical and ethnic populations, different individuals within these populations, different tumour foci within the same patient, and different cells within the same tumour focus. The highly heterogeneous nature of prostate cancer provides a real challenge for clinical disease management and a detailed understanding of the genetic alterations in all cells, including small subpopulations, would be highly advantageous.

Citing Articles

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.

Khorasanchi A, Hong F, Yang Y, Singer E, Wang P, Li M Cancer Drug Resist. 2025; 8:9.

PMID: 40051495 PMC: 11883235. DOI: 10.20517/cdr.2024.173.


Heterogeneity of cancer-associated fibroblast subpopulations in prostate cancer: Implications for prognosis and immunotherapy.

Ding C, Wang J, Wang J, Niu J, Xiahou Z, Sun Z Transl Oncol. 2024; 52():102255.

PMID: 39721245 PMC: 11732565. DOI: 10.1016/j.tranon.2024.102255.


Effect of subcutaneous adipose tissue-associated CSRP2 on the progression of prostate cancer via the WDR5/USP44 pathway.

Wang J, Liang Y, Wang K, Lin L, Peng X, Li W Am J Cancer Res. 2024; 14(11):5321-5337.

PMID: 39659944 PMC: 11626258. DOI: 10.62347/AHQT5920.


Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects.

Jiang Y, Wang C, Zu C, Rong X, Yu Q, Jiang J Int J Nanomedicine. 2024; 19:9459-9486.

PMID: 39371481 PMC: 11456300. DOI: 10.2147/IJN.S466396.


Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management.

Kulasegaran T, Oliveira N Curr Treat Options Oncol. 2024; 25(7):914-931.

PMID: 38913213 PMC: 11236885. DOI: 10.1007/s11864-024-01215-2.


References
1.
Dong J . Prevalent mutations in prostate cancer. J Cell Biochem. 2005; 97(3):433-47. DOI: 10.1002/jcb.20696. View

2.
Humphrey P . Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004; 17(3):292-306. DOI: 10.1038/modpathol.3800054. View

3.
Qian J, Jenkins R, Bostwick D . Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Urology. 1995; 46(6):837-42. DOI: 10.1016/S0090-4295(99)80354-9. View

4.
Xu J . Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet. 2000; 66(3):945-57. PMC: 1288175. DOI: 10.1086/302807. View

5.
Villers A, McNeal J, Freiha F, Stamey T . Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer. 1992; 70(9):2313-8. DOI: 10.1002/1097-0142(19921101)70:9<2313::aid-cncr2820700917>3.0.co;2-t. View